论文部分内容阅读
目的:评价阿德福韦酯(ADV)联合聚乙二醇干扰素α-2a(PEGα-2a)治疗HBeAg阳性慢性乙肝患者(CHB)的疗效。方法:将2010年4月—2012年2月间收治的60例HBeAg阳性CHB分为观察组(n=30)和对照组(n=30);观察组采用ADV联合PEGα-2a治疗,对照组采用PEGα-2a治疗,观察其疗效。结果:经治疗后观察组ALT、TBIl、AST和ALB水平值以及ALT复常率、HBV-DNA转阴率、HBeAg转阴率和HBeAg血清转换率值均显著高于对照组,其差异有统计学意义(P<0.05);但两组患者并发症的发生率,经统计学分析,其差异无统计学意义(P<0.05)。结论:此治疗法对HBeAg阳性CHB疗效确切,值得临床推广应用。
Objective: To evaluate the efficacy of adefovir dipivoxil (ADV) in combination with pegylated interferon α-2a (PEGα-2a) in the treatment of CHB patients with HBeAg-positive chronic hepatitis B. Methods: Sixty HBeAg positive CHB patients who were treated between April 2010 and February 2012 were divided into observation group (n = 30) and control group (n = 30). The observation group was treated with ADV combined with PEGα-2a and the control group The use of PEGα-2a treatment, observe its efficacy. Results: After treatment, the levels of ALT, TBIl, AST and ALB, as well as ALT normalization rate, HBV-DNA negative rate, HBeAg negative rate and HBeAg seroconversion rate in the observation group were significantly higher than those in the control group (P <0.05). However, the incidence of complications in both groups was not statistically significant (P <0.05) by statistical analysis. Conclusion: The treatment of HBeAg-positive CHB curative effect is worthy of clinical application.